Is Big Pharma Ignoring Small Biotech?

Recent news might have you believe Big Pharma is turning its back on innovation hubs like small-cap biotech companies. Headlines scream about “dying deals” and a “broken acquisition market,” depicting a pharma giant spurning the next blockbuster cure. While sales potential undoubtedly influences biotech companies’ acquisition, it’s not the only criterion.

Here’s why the “Big Pharma vs. Small Biotech” narrative might be missing the mark:

Website